Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China | Stem Cells Course

Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China

The Global Stem Cells Group has established a collaborative alliance with HANK Bioengineering Co., Ltd. of Shenzhen, China.

Global Stem Cells has announced a newly formed alliance with Shenzhen HANK Bioengineering Co., Ltd. and its Chinese-American founder Mingjie Zhang, M.D., Ph.D. The alliance will establish a stem cells training course in the City of Shenzen, Guangdong Province, China in September 2015.

Shenzhen HANK is a biotechnology company established in 2013 by Zhang, an award-winning scientist, microbiologist and virologist, to integrate research, development, production, and sales of biomedical products. Zhang worked at the U.S. Centers for Disease Control from 1991 to 1993, the U.S. National Institute of Health (NIH) from 1993 to 1994, and the U.S. Food and Drug Administration from 1995 to 2013 in various research positions including National Research Center (NRC) senior associate from 1995 to 1997. In 2012 he earned the Scientific Achievement Award from the USFDA for outstanding achievement in natural killer (NK) cell research, and holds numerous awards for his work in the fields of HIV, HCV, West Nile virus, Japanese encephalitis virus, and quality performance.

In 2013, Dr. Zhang expanded on his work in stem cell research and development by launching HANK Bioengineering Co. Ltd. in Shenzhen, China. HANK is a 4,300 square foot (400 square meters) CFDA certified cGMP facility affiliated with HANK Bioengineering Institute’s Cell Biology and Molecular Immunology Laboratories. HANK has established close collaborations with more than five hospitals in China for clinical applications of its cell therapy products.

Shenzhen HANK is also a biotechnology service provider committed to the development and application of multiple immune cell therapy systems. The company has up to 20 cell therapy products of 4 series approved by the CFDA, including lymphocyte culture medium (NK, CTL and Treg cell in vitro culture reagents), lymphocyte serum-free culture medium, lymphocyte separation media, and lymphocyte freezing medium.

“Dr. Zhang and HANK Bioengineering will work seamlessly with our research, product development and education programs,” says Benito Novas, Global Stem Cells Group CEO. “This is a great opportunity for us to expand into China and work with one of the world’s most accomplished cell therapy researchers in his certified, cutting-edge cell biology laboratories.”